Vizsgálati helyszín
Vivamed Sp. z o.o.
Warsaw, 03-580, LengyelországEU-13 felzárkózó országMég nincs intézményhez kötve
- 18futó vizsgálat
- 2lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 20 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis11 vizsgálat
- 2. fázis8 vizsgálat
- 2/3. fázis1 vizsgálat
- Állapot
- Fut, nem toboroz11 vizsgálat
- Toboroz7 vizsgálat
- Lezárult2 vizsgálat
- Fő szponzor
- Janssen Research & Development, LLC4 vizsgálat
- AbbVie3 vizsgálat
- Eli Lilly and Company3 vizsgálat
- Merck Sharp & Dohme LLC3 vizsgálat
- Hoffmann-La Roche2 vizsgálat
- és még 4
Futó vizsgálatok
Toboroz
A Phase 2 Platform Study to Evaluate Therapies for Inflammatory Bowel Disease
2025-522001-38-00· 2. fázis· Mirador Therapeutics Inc.· Forrás
Toboroz
A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)
NCT07463183· 2. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008)
2024-518296-56-00· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
NCT06937099· 3. fázis· Eli Lilly and Company· Forrás
Contact: Robert Petryka (principal investigator)
Toboroz
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
NCT06937086· 3. fázis· Eli Lilly and Company· Forrás
Contact: Jakub Slowik (principal investigator)
Toboroz
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819891· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06588855· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
NCT06456593· 2. fázis· Abivax S.A.· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
NCT06430801· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06290934· 2. fázis· Gilead Sciences· Forrás
Fut, nem toboroz
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05242484· 2. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
NCT05242471· 2. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease
NCT05197049· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis
NCT03398135· 3. fázis· AbbVie· Forrás
Fut, nem toboroz
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
NCT03519945· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
NCT03466411· 2/3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
NCT03105102· 3. fázis· AbbVie· Forrás
Fut, nem toboroz
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
NCT03006068· 3. fázis· AbbVie· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek